BioSpace News Archive

Drug Development

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European BMT Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society being held April 14 – 17, 2024, in Glasgow, Scotland.

April 1, 2024
·
5 min read
Business

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

April 1, 2024
·
6 min read
Drug Development

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium, Inc. today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients.

April 1, 2024
·
9 min read
Bio NC

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

April 1, 2024
·
2 min read
Business

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

April 1, 2024
·
16 min read
BioMidwest

PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1

PharmaJet® announced the formation of two Scientific Advisory Boards comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping.

April 1, 2024
·
5 min read
Drug Development

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.

April 1, 2024
·
9 min read
Business

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.

April 1, 2024
·
18 min read
Drug Development

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Vistagen today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).

April 1, 2024
·
7 min read
Business

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Biomea Fusion, Inc. reported fourth quarter and full year 2023 financial results and corporate highlights.

April 1, 2024
·
14 min read